About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3035835
Allelic
Composition
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (7 available); any Kras mutation (36 available)
Tg(Mx1-cre)1Cgn mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• 7 of 25 mice injected with pIpC develop thymic T cell lymphoblastic lymphomas
• 2 of 6 non pIpC treated mice show thymic lymphomas

respiratory system
• 10 of 17 mice injected with pIpC exhibit multiple nodules in the lungs consisting of proliferating type II penumocytes
• 5 of 6 non pIpC treated mice show pulmonary adenomas

digestive/alimentary system
• 8 of 22 mice injected with pIpC develop squamous papillomas involving the esophageal mucosa
• 8 of 25 mice injected with pIpC develop squamous papillomas involving the oral mucosa
• 2 of 6 non-pIpC treated mice show oral squamous papillomas

mortality/aging
• survival for around 35 days after pI-pC treatment
• survival of around 58 days even without pI-pC treatment

neoplasm
• 7 of 25 mice injected with pIpC develop thymic T cell lymphoblastic lymphomas
• 2 of 6 non pIpC treated mice show thymic lymphomas
• 10 of 17 mice injected with pIpC exhibit multiple nodules in the lungs consisting of proliferating type II penumocytes
• 5 of 6 non pIpC treated mice show pulmonary adenomas
• squamous papillomas
• 8 of 22 mice injected with pIpC develop squamous papillomas involving the esophageal mucosa
• 8 of 25 mice injected with pIpC develop squamous papillomas involving the oral mucosa
• 2 of 6 non-pIpC treated mice show oral squamous papillomas
• 12 of 19 mice injected with pIpC develop squamous papillomas involving the anal and vulvo-vaginal skin and 8 of 22 mice develop squamous papillomas involving the ear
• 2 of 6 non-pIpC treated mice show ear squamous papillomas

growth/size/body
• becoming emaciated

hematopoietic system
• develop lethal hematopoietic disease
• 4-7 week old mice injected with pIpC develop a myeloproliferative disorder
• bone marrow of mice injected with pIpC shows myelomonocytic expansion
• all mice that are not treated with pIpC also develop a hematopoietic disease, however these mice exhibit expression of the mutant Kras, indicating that most likely endogenous IFN expression is sufficient to induce the cre transgene
• bone marrow cells from pIpC injected mice readily form colonies, predominately monocyte colony-forming units (M-CFUs) in a growth factor-independent manner unlike controls
• myeloproliferative phenotype
• myeloid hyperplasia of bone marrow
• expansion of red pulp in spleen by granulocyte/monocyte lineages in 11 out of 16 cases
• erythroid expansion was seen in red pulp of spleen in 5 of 16 cases
• the liver shows perivascular and periportal infiltration by myeloid and erythroid cell populations
• mice injected with pIpC become anemic
• mice injected with pIpC have a mean hematocrit of 27% compared with 45% in controls
• leukocytosis, usually involving increases in granulocytes, in both pIpC and non-pIpC treated mice
• leukocytosis in mice injected with pIpC is mainly due to an increase in granulocyte population
• mice injected with pIpC show expansion of the red pulp by varying degrees of granulocytic
• mice injected with pIpC develop moderate to severe splenomegaly

immune system
• 4-7 week old mice injected with pIpC develop a myeloproliferative disorder
• bone marrow of mice injected with pIpC shows myelomonocytic expansion
• all mice that are not treated with pIpC also develop a hematopoietic disease, however these mice exhibit expression of the mutant Kras, indicating that most likely endogenous IFN expression is sufficient to induce the cre transgene
• bone marrow cells from pIpC injected mice readily form colonies, predominately monocyte colony-forming units (M-CFUs) in a growth factor-independent manner unlike controls
• myeloproliferative phenotype
• myeloid hyperplasia of bone marrow
• leukocytosis, usually involving increases in granulocytes, in both pIpC and non-pIpC treated mice
• leukocytosis in mice injected with pIpC is mainly due to an increase in granulocyte population
• mice injected with pIpC show expansion of the red pulp by varying degrees of granulocytic
• mice injected with pIpC develop moderate to severe splenomegaly
• 6 of 17 mice injected with pIpC develop nodal lymphoid hyperplasia

liver/biliary system
• perivascular and periportal infiltration in liver by myeloid and erythroid cells similar to what is seen in spleen

integument
• ruffled fur
• 12 of 19 mice injected with pIpC develop squamous papillomas involving the anal and vulvo-vaginal skin and 8 of 22 mice develop squamous papillomas involving the ear
• 2 of 6 non-pIpC treated mice show ear squamous papillomas

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
juvenile myelomonocytic leukemia DOID:0050458 OMIM:607785
J:88163


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/18/2020
MGI 6.14
The Jackson Laboratory